Federal Circuit says biosimilar applicants can decline patent dance
The Federal Circuit in Amgen v Sandoz was split two ways, holding biosimilar applicants can opt out of the patent dance provisions but must wait for approval before giving 180 days notice of marketing. Applicants and patent owners now face tricky strategic questions
In a decision seen as favouring biosimilar applicants over so-called reference product sponsors (RPSs), the Federal Circuit has dismissed Amgen’s state law claims against Sandoz related to the first approved biosimilar product. This has cleared the way for Sandoz to...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.